[go: up one dir, main page]

JOP20200201A1 - تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين - Google Patents

تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين

Info

Publication number
JOP20200201A1
JOP20200201A1 JOP/2020/0201A JOP20200201A JOP20200201A1 JO P20200201 A1 JOP20200201 A1 JO P20200201A1 JO P20200201 A JOP20200201 A JO P20200201A JO P20200201 A1 JOP20200201 A1 JO P20200201A1
Authority
JO
Jordan
Prior art keywords
quinoxalin
dimethoxyphenyl
pyrazol
methylethyl
ethane
Prior art date
Application number
JOP/2020/0201A
Other languages
English (en)
Inventor
Diego Fernando Domenico Broggini
Original Assignee
Astex Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=55442769&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JOP20200201(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astex Therapeutics Ltd filed Critical Astex Therapeutics Ltd
Publication of JOP20200201A1 publication Critical patent/JOP20200201A1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
    • C09K—MATERIALS FOR MISCELLANEOUS APPLICATIONS, NOT PROVIDED FOR ELSEWHERE
    • C09K15/00—Anti-oxidant compositions; Compositions inhibiting chemical change
    • C09K15/04—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds
    • C09K15/20—Anti-oxidant compositions; Compositions inhibiting chemical change containing organic compounds containing nitrogen and oxygen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Materials Engineering (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع بتركيبات صيدلانية تشتمل على N- (3، 5- داي ميثوكسي فينيل) -Nَ- (1- ميثيل إيثيل) -N- [3- (1- ميثيل -1H- بيرازول -4- يل) كينوكسالين -6- يل] إيثان -1، 2- داي أمين، أو ملح مقبول صيدلانياً منه أو ذوابة منه؛ وبعمليات لتحضير التركيبات المذكورة وباستعمال التركيبات المذكورة لتصنيع دواء للوقاية من أو علاج الأمراض، وبالتحديد علاج أمراض مثل السرطان.
JOP/2020/0201A 2015-02-10 2015-02-10 تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين JOP20200201A1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15154554 2015-02-10
EP15188982 2015-10-08

Publications (1)

Publication Number Publication Date
JOP20200201A1 true JOP20200201A1 (ar) 2017-06-16

Family

ID=55442769

Family Applications (2)

Application Number Title Priority Date Filing Date
JOP/2020/0201A JOP20200201A1 (ar) 2015-02-10 2015-02-10 تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
JOP/2016/0022A JO3695B1 (ar) 2015-02-10 2016-02-03 تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)

Family Applications After (1)

Application Number Title Priority Date Filing Date
JOP/2016/0022A JO3695B1 (ar) 2015-02-10 2016-02-03 تركيبات صيدلانية تشتمل على n- (3.5- ثنائي ميثوكسي فينيل)-n-(1-ميثيل إيثيل)-n- 3-( ميثيل-h1-بيرازول-4-يل) كينوكسالين-6-يل) إيثان- 1.2-ثنائي الأمين)

Country Status (32)

Country Link
US (3) US10898482B2 (ar)
EP (2) EP3256109B1 (ar)
JP (3) JP6796588B2 (ar)
KR (2) KR102900539B1 (ar)
CN (2) CN113209102A (ar)
AU (3) AU2016218000B2 (ar)
BR (1) BR112017017009B1 (ar)
CA (1) CA2976356A1 (ar)
CL (1) CL2017002022A1 (ar)
CO (1) CO2017008862A2 (ar)
CR (1) CR20170411A (ar)
CY (1) CY1124432T1 (ar)
DK (1) DK3256109T3 (ar)
ES (1) ES2883829T3 (ar)
HR (1) HRP20211244T1 (ar)
HU (1) HUE056761T2 (ar)
IL (3) IL310469B2 (ar)
JO (2) JOP20200201A1 (ar)
LT (1) LT3256109T (ar)
MA (2) MA41496B1 (ar)
MX (2) MX381504B (ar)
MY (1) MY196599A (ar)
NI (1) NI201700101A (ar)
PH (2) PH12017501421B1 (ar)
PL (1) PL3256109T3 (ar)
RS (1) RS62221B1 (ar)
SG (2) SG11201706472RA (ar)
SI (1) SI3256109T1 (ar)
SM (1) SMT202100450T1 (ar)
TW (2) TWI834020B (ar)
UA (1) UA123767C2 (ar)
WO (1) WO2016128411A1 (ar)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
JOP20200201A1 (ar) * 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
ES2904513T3 (es) 2015-09-23 2022-04-05 Janssen Pharmaceutica Nv 1,4-Benzodiazepinas biheteroarilo sustituidas y usos de las mismas para el tratamiento del cáncer
EP3353177B1 (en) 2015-09-23 2020-06-03 Janssen Pharmaceutica NV Tricyclic heterocycles for the treatment of cancer
JOP20190190A1 (ar) * 2017-02-06 2019-08-04 Janssen Pharmaceutica Nv معالجة سرطان
EA201991818A1 (ru) * 2017-12-20 2020-02-05 Янссен Фармацевтика Нв Лечение рака
WO2019199133A1 (ko) 2018-04-13 2019-10-17 주식회사 삼양바이오팜 레날리도마이드의 경구용 코팅 정제 조성물
CN118873536A (zh) * 2018-08-31 2024-11-01 细胞内治疗公司 新方法
CA3126959A1 (en) * 2019-02-12 2020-08-20 Janssen Pharmaceutica Nv Cancer treatment
US20230110113A1 (en) * 2020-02-12 2023-04-13 Janssen Pharmaceutica Nv Fgfr tyrosine kinase inhibitors for the treatment of high-risk non-muscle invasive bladder cancer
MX2024004488A (es) 2021-10-12 2024-07-10 Taris Biomedical Llc Formulaciones y sistemas de erdafitinib para administración intravesical.
JP2025507590A (ja) 2022-02-18 2025-03-21 タリス バイオメディカル エルエルシー エルダフィチニブ製剤及び膀胱内投与のための浸透圧システム
CA3246820A1 (en) * 2022-04-07 2023-10-12 Natco Pharma Limited STABLE PHARMACEUTICAL COMPOSITIONS CONTAINING ERDAFITINIB
EP4665342A1 (en) 2023-02-13 2025-12-24 TARIS Biomedical LLC Erdafitinib for intravesical administration for use in the treatment of bladder cancer
EP4665343A1 (en) 2023-02-17 2025-12-24 TARIS Biomedical LLC Erdafitinib for intravesical administration for use in the treatment of bladder cancer

Family Cites Families (179)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2940972A (en) 1957-06-27 1960-06-14 Thomae Gmbh Dr K Tri-and tetra-substituted pteridine derivatives
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
US5710158A (en) 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9125001D0 (en) 1991-11-25 1992-01-22 Ici Plc Heterocyclic compounds
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
AU6909194A (en) 1993-05-14 1994-12-12 Board Of Regents, The University Of Texas System Preparation of n-cyanodithioimino-carbonates and 3-mercapto-5-amino-1h-1,2,4-triazole
US5700823A (en) 1994-01-07 1997-12-23 Sugen, Inc. Treatment of platelet derived growth factor related disorders such as cancers
IL115256A0 (en) 1994-11-14 1995-12-31 Warner Lambert Co 6-Aryl pyrido (2,3-d) pyrimidines and naphthyridines and their use
US6331555B1 (en) 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
EP0951541B1 (en) 1995-07-31 2005-11-30 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
KR100466955B1 (ko) 1996-02-26 2005-06-10 에자이 가부시키가이샤 항종양제함유조성물
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
ES2235331T3 (es) 1997-05-28 2005-07-01 Aventis Pharmaceuticals Inc Compuestos quinolina y quinoxalina que inhiben el factor de crecimiento derivado de plaquetas y/o tirosina quinasas p561ck.
US6235740B1 (en) 1997-08-25 2001-05-22 Bristol-Myers Squibb Co. Imidazoquinoxaline protein tyrosine kinase inhibitors
UA71555C2 (en) 1997-10-06 2004-12-15 Zentaris Gmbh Methods for modulating function of serine/threonine protein kinases by 5-azaquinoline derivatives
AU1918299A (en) 1998-02-23 1999-09-06 Warner-Lambert Company Substituted quinoxaline derivatives as interleukin-8 receptor antagonists
EP1147094A1 (en) 1999-01-15 2001-10-24 Novo Nordisk A/S Non-peptide glp-1 agonists
CA2372990C (en) 1999-05-05 2007-06-19 Institut Curie Means for detecting and treating pathologies linked to fgfr3
US7135311B1 (en) 1999-05-05 2006-11-14 Institut Curie Means for detecting and treating pathologies linked to FGFR3
CN1373763A (zh) 1999-09-15 2002-10-09 沃尼尔·朗伯公司 作为激酶抑制剂的蝶啶酮
DE10013318A1 (de) 2000-03-17 2001-09-20 Merck Patent Gmbh Formulierung enthaltend Chinoxalinderivate
WO2002076985A1 (en) 2001-03-23 2002-10-03 Smithkline Beecham Corporation Compounds useful as kinase inhibitors for the treatment of hyperproliferative diseases
US20030235628A1 (en) 2001-09-19 2003-12-25 Rajneesh Taneja Methods and pharmaceutical formulations for protecting pharmaceutical compounds from acidic environments
DE60223720T2 (de) 2001-12-18 2008-10-30 Merck & Co., Inc. Heteroaryl-substituierte pyrazol-modulatoren des metabotropen glutamatrezeptors-5
CN101973998A (zh) 2001-12-20 2011-02-16 Osi药物公司 吡咯并嘧啶A2b选择性拮抗剂化合物
RU2323215C2 (ru) 2001-12-24 2008-04-27 Астразенека Аб Замещенные производные хиназолина как ингибиторы ауроракиназы
JP2003213463A (ja) 2002-01-17 2003-07-30 Sumitomo Chem Co Ltd 金属腐食防止剤および洗浄液
CA2480800C (en) 2002-04-08 2008-09-23 Mark T. Bilodeau Inhibitors of akt activity
US20040097725A1 (en) 2002-07-10 2004-05-20 Norman Herron Charge transport compositions and electronic devices made with such compositions
PA8577501A1 (es) 2002-07-25 2004-02-07 Warner Lambert Co Inhibidores de quinasas
US7825132B2 (en) 2002-08-23 2010-11-02 Novartis Vaccines And Diagnostics, Inc. Inhibition of FGFR3 and treatment of multiple myeloma
BR0315053A (pt) 2002-10-03 2005-08-09 Targegen Inc Agentes vasculostáticos , composição, artigo e processo de preparação dos mesmos
EP1559433A4 (en) 2002-10-22 2009-11-04 Dainippon Sumitomo Pharma Co STABILIZED COMPOSITION
AR043059A1 (es) 2002-11-12 2005-07-13 Bayer Pharmaceuticals Corp Derivados de indolil pirazinona utiles para el tratamiento de trastornos hiper-proliferativos
US7098332B2 (en) 2002-12-20 2006-08-29 Hoffmann-La Roche Inc. 5,8-Dihydro-6H-pyrido[2,3-d]pyrimidin-7-ones
DE602004021558D1 (de) 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
US20040204450A1 (en) 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
WO2004098494A2 (en) 2003-04-30 2004-11-18 Cytokinetics, Inc. Compounds, compositions, and methods
MXPA05012281A (es) 2003-05-14 2006-05-19 Torreypines Therapeutics Inc Compuestos y uso de los mismos en la modulacion beta amiloide.
DE10323345A1 (de) 2003-05-23 2004-12-16 Zentaris Gmbh Neue Pyridopyrazine und deren Verwendung als Kinase-Inhibitoren
AU2004240747B2 (en) 2003-05-23 2008-01-03 Zentaris Gmbh Novel pyridopyrazines and use thereof as kinase modulators
WO2005007099A2 (en) 2003-07-10 2005-01-27 Imclone Systems Incorporated Pkb inhibitors as anti-tumor agents
CA2533417A1 (en) 2003-07-21 2005-02-03 Mitchell A. Avery Design and synthesis of optimized ligands for ppar
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
DK1673092T3 (da) 2003-10-17 2007-12-17 4 Aza Ip Nv Heterocyklylsubstituerede pteridinderivater og anvendelsen deraf i terapi
EP1694308A1 (en) 2003-10-30 2006-08-30 Lupin Ltd. Stable formulations of ace inhibitors and methods for preparation thereof
EP1682529A4 (en) 2003-11-07 2010-06-30 Novartis Vaccines & Diagnostic PROCESS FOR SYNTHESIS OF CHINOLINONE COMPOUNDS
AU2004295058B9 (en) 2003-11-20 2011-06-30 Janssen Pharmaceutica N.V. 6-alkenyl and 6-phenylalkyl substituted 2-quinolinones and 2-quinoxalinones as poly(ADP-ribose) polymerase inhibitors
WO2005054231A1 (en) 2003-11-24 2005-06-16 F.Hoffmann-La Roche Ag Pyrazolyl and imidazolyl pyrimidines
US8247576B2 (en) 2003-12-23 2012-08-21 Astex Therapeutics Limited Pyrazole derivatives as protein kinase modulators
US7098222B2 (en) 2004-05-12 2006-08-29 Abbott Laboratories Bicyclic-substituted amines having cyclic-substituted monocyclic substituents
US7205316B2 (en) 2004-05-12 2007-04-17 Abbott Laboratories Tri- and bi-cyclic heteroaryl histamine-3 receptor ligands
US7446196B2 (en) 2004-06-03 2008-11-04 Kosan Biosciences, Incorporated Leptomycin compounds
US20090118261A1 (en) 2004-08-31 2009-05-07 Astrazeneca Ab Quinazolinone derivatives and their use as b-raf inhibitors
CA2583192A1 (en) 2004-10-14 2006-04-20 F. Hoffmann-La Roche Ag 1,5-naphthyridine azolidinones having cdk1 antiproliferative activity
CA2583096A1 (en) 2004-10-15 2006-04-20 Astrazeneca Ab Quinoxalines as b raf inhibitors
EP1659175A1 (en) 2004-11-18 2006-05-24 Institut Curie Alterations in seborrheic keratoses and their applications
NZ555701A (en) 2004-12-09 2011-05-27 Insys Therapeutics Inc Room-temperature stable dronabinol formulations
CN102049048B (zh) 2004-12-24 2013-12-25 西芬克斯医药有限公司 治疗或预防的方法
EP1833469A2 (en) 2005-01-03 2007-09-19 Lupin Ltd. Pharmaceutical composition of acid labile substances
CA2597447C (en) 2005-02-14 2014-03-25 Bionomics Limited Novel tubulin polymerisation inhibitors
US9271963B2 (en) 2005-03-03 2016-03-01 Universitat Des Saarlandes Selective inhibitors of human corticosteroid synthases
US20090156617A1 (en) 2005-05-12 2009-06-18 Northrup Alan B Tyrosine kinase inhibitors
ZA200710313B (en) 2005-05-13 2009-05-27 Topotarget Uk Ltd Pharmaceutical formulations of HDAC inhibitors
MX2007014258A (es) 2005-05-18 2008-01-22 Wyeth Corp Inhibidores de 4,6-diamino-[1,7]naftiridin-3-carbonitrilo de la tpl2 cinasa y metodos de fabricacion y uso de los mismos.
US8945543B2 (en) 2005-06-10 2015-02-03 Chugai Seiyaku Kabushiki Kaisha Stabilizer for protein preparation comprising meglumine and use thereof
GB0513692D0 (en) 2005-07-04 2005-08-10 Karobio Ab Novel pharmaceutical compositions
ES2456000T3 (es) 2005-08-26 2014-04-21 Merck Serono Sa Derivados de pirazina y su uso como inhibidores de PI3K
CN103819416A (zh) 2005-10-07 2014-05-28 埃克塞里艾克西斯公司 N-(3-氨基-喹喔啉-2-基)-磺酰胺衍生物及其作为磷脂酰肌醇3-激酶抑制剂的用途
EP1790342A1 (de) 2005-11-11 2007-05-30 Zentaris GmbH Pyridopyrazin-Derivate und deren Verwendung als Modulatoren der Signaltransduktionswege
JP5527972B2 (ja) 2005-11-11 2014-06-25 エテルナ ツェンタリス ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のピリドピラジン及び前記ピリドピラジンをキナーゼのモジュレーターとして用いる使用
US8217042B2 (en) 2005-11-11 2012-07-10 Zentaris Gmbh Pyridopyrazines and their use as modulators of kinases
CN1966500B (zh) 2005-11-17 2011-03-30 中国科学院上海药物研究所 一类喹喔啉类衍生物、制法及用途
US20090247576A1 (en) 2005-11-22 2009-10-01 Eisai R & D Management Co., Ltd. Anti-tumor agent for multiple myeloma
RS55630B1 (sr) 2005-12-21 2017-06-30 Janssen Pharmaceutica Nv Triazolopiridazini kao modulatori tirozin kinaze
TW200808739A (en) 2006-04-06 2008-02-16 Novartis Vaccines & Diagnostic Quinazolines for PDK1 inhibition
JP2009535393A (ja) 2006-05-01 2009-10-01 ファイザー・プロダクツ・インク 置換２−アミノ縮合複素環式化合物
GB0609621D0 (en) 2006-05-16 2006-06-21 Astrazeneca Ab Novel co-crystal
ATE549338T1 (de) 2006-05-24 2012-03-15 Boehringer Ingelheim Int Substituierte pteridine, die mit einem viergliedrigen heterocyclus substituiert sind
JO3235B1 (ar) 2006-05-26 2018-03-08 Astex Therapeutics Ltd مركبات بيررولوبيريميدين و استعمالاتها
CA2657702A1 (en) 2006-07-03 2008-01-10 Vereniging Voor Christelijk Hoger Onderwijs Wetenschappelijk Onderzoek E N Patieentenzorg Quinazolines and related heterocyclic comp0unds, and their therapeutic use
CA2658725A1 (en) 2006-08-16 2008-02-21 Exelixis, Inc. Using pi3k and mek modulators in treatments of cancer
EP2081928B1 (en) 2006-11-10 2014-02-26 Bristol-Myers Squibb Company Pyrrolo-pyridine kinase inhibitors
JP2008127446A (ja) 2006-11-20 2008-06-05 Canon Inc １，５−ナフチリジン化合物及び有機発光素子
WO2008076278A2 (en) 2006-12-13 2008-06-26 Schering Corporation Methods of cancer treatment with igf1r inhibitors
US7872018B2 (en) 2006-12-21 2011-01-18 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
US20100216767A1 (en) 2006-12-22 2010-08-26 Mina Aikawa Quinazolines for pdk1 inhibition
MX2009006706A (es) 2006-12-22 2009-07-02 Astex Therapeutics Ltd Compuestos heterociclicos biciclicos como inhibidores del receptor del factor de crecimiento de fibroblastos.
KR20080062876A (ko) 2006-12-29 2008-07-03 주식회사 대웅제약 신규한 항진균성 트리아졸 유도체
WO2008109369A2 (en) 2007-03-02 2008-09-12 Mdrna, Inc. Nucleic acid compounds for inhibiting tnf gene expression and uses thereof
US8163923B2 (en) 2007-03-14 2012-04-24 Advenchen Laboratories, Llc Spiro substituted compounds as angiogenesis inhibitors
TW200902008A (en) 2007-05-10 2009-01-16 Smithkline Beecham Corp Quinoxaline derivatives as PI3 kinase inhibitors
EP1990342A1 (en) 2007-05-10 2008-11-12 AEterna Zentaris GmbH Pyridopyrazine Derivatives, Process of Manufacturing and Uses thereof
US20100179143A1 (en) 2007-05-29 2010-07-15 Smithkline Beecham Corporation Naphthyridine, derivatives as p13 kinase inhibitors
AR066879A1 (es) 2007-06-08 2009-09-16 Novartis Ag Derivados de quinoxalina como inhibidores de la actividad de cinasa de tirosina de las cinasas janus
BRPI0813105A2 (pt) 2007-06-20 2015-08-04 Mitsubishi Tanabe Pharma Corp Derivado de sulfonamida de ácido malônico e uso faramacêutico do mesmo
EP2170894A1 (en) 2007-06-21 2010-04-07 Janssen Pharmaceutica N.V. Polymorphic and hydrate forms, salts and process for preparing 6-{difluoro[6-(1-methyl-1h-pyrazol-4-yl)[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}quinoline
US20090263397A1 (en) 2007-07-06 2009-10-22 Buck Elizabeth A Combination anti-cancer therapy
RU2472797C2 (ru) 2007-08-08 2013-01-20 ГЛАКСОСМИТКЛАЙН ЭлЭлСи ПРОИЗВОДНЫЕ 2-[(2-(ФЕНИЛАМИНО)-1Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АМИНО]БЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ IGF-1R ДЛЯ ЛЕЧЕНИЯ РАКА
WO2009019518A1 (en) 2007-08-09 2009-02-12 Astrazeneca Ab Pyrimidine compounds having a fgfr inhibitory effect
JP2010535804A (ja) 2007-08-09 2010-11-25 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｐｉ３キナーゼ阻害薬としてのキノキサリン誘導体
WO2013173485A1 (en) 2012-05-15 2013-11-21 Predictive Biosciences, Inc. Detection of bladder cancers
US20090054304A1 (en) 2007-08-23 2009-02-26 Kalypsys, Inc. Heterocyclic modulators of tgr5 for treatment of disease
US8309718B2 (en) 2007-11-16 2012-11-13 Incyte Corporation 4-pyrazolyl-N-arylpyrimidin-2-amines and 4-pyrazolyl-N-heteroarylpyrimidin-2-amines as janus kinase inhibitors
DK2234600T3 (da) 2007-12-21 2014-09-08 Hoffmann La Roche Antistofformulering
WO2009137378A2 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
MY161597A (en) 2008-11-15 2017-04-28 Rib-X Pharmaceuticals Inc Antimicrobial compositions
JP2012509342A (ja) 2008-11-20 2012-04-19 オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド 置換ピロロ［２，３−ｂ］−ピリジンおよび−ピラジン
CA2750047A1 (en) 2009-01-21 2010-07-29 Basilea Pharmaceutica Ag Novel bicyclic antibiotics
JP2012516847A (ja) 2009-02-02 2012-07-26 メルク・シャープ・エンド・ドーム・コーポレイション Ａｋｔ活性の阻害剤
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
FR2945950A1 (fr) 2009-05-27 2010-12-03 Elan Pharma Int Ltd Compositions de nanoparticules anticancereuses et procedes pour les preparer
MX353776B (es) 2009-06-12 2018-01-29 Abivax Compuestos utiles para tratar cancer.
ES2534226T3 (es) 2009-09-03 2015-04-20 Bioenergenix Compuestos heterocíclicos para la inhibición de PASK
US9340528B2 (en) 2009-09-04 2016-05-17 Bayer Pharma Aktiengesellschaft Substituted aminoquinoxalines as tyrosine threonine kinase inhibitors
ES2625731T3 (es) 2009-09-18 2017-07-20 Sanofi Formulaciones de tabletas de la (Z)-(4¿-trifluorometilfenil)-amida del ácido 2-ciano-3-hidroxi-but-2-enoico con estabilidad mejorada
US20110123545A1 (en) 2009-11-24 2011-05-26 Bristol-Myers Squibb Company Combination of vegfr2 and igf1r inhibitors for the treatment of proliferative diseases
EP2332939A1 (en) 2009-11-26 2011-06-15 Æterna Zentaris GmbH Novel Naphthyridine derivatives and the use thereof as kinase inhibitors
SG10201502484SA (en) 2010-03-30 2015-05-28 Verseon Corp Multisubstituted aromatic compounds as inhibitors of thrombin
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US8513421B2 (en) 2010-05-19 2013-08-20 Millennium Pharmaceuticals, Inc. Substituted hydroxamic acids and uses thereof
WO2011149937A1 (en) 2010-05-24 2011-12-01 Intellikine, Inc. Heterocyclic compounds and uses thereof
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
CN102532141A (zh) 2010-12-08 2012-07-04 中国科学院上海药物研究所 [1，2，4]三唑并[4，3-b][1，2，4]三嗪类化合物、其制备方法和用途
AU2012213080B2 (en) 2011-01-31 2014-03-27 Novartis Ag Novel heterocyclic derivatives
JP2014510265A (ja) 2011-02-02 2014-04-24 アムジェン インコーポレイテッド Ｉｇｆ−１ｒの阻害に関する方法および組成物
TWI592411B (zh) 2011-02-23 2017-07-21 英特爾立秦有限責任公司 激酶抑制劑之組合及其用途
WO2012118492A1 (en) 2011-03-01 2012-09-07 Array Biopharma Inc. Heterocyclic sulfonamides as raf inhibitors
WO2012149014A1 (en) 2011-04-25 2012-11-01 OSI Pharmaceuticals, LLC Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment
CN107245056A (zh) 2011-08-26 2017-10-13 润新生物公司 化学实体、组合物及方法
US9518029B2 (en) 2011-09-14 2016-12-13 Neupharma, Inc. Certain chemical entities, compositions, and methods
EP2757885B1 (en) 2011-09-21 2017-03-15 Neupharma, Inc. Certain chemical entites, compositions, and methods
US20130096021A1 (en) 2011-09-27 2013-04-18 Arul M. Chinnaiyan Recurrent gene fusions in breast cancer
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
JO3210B1 (ar) 2011-10-28 2018-03-08 Merck Sharp & Dohme مثبط منصهر لبروتين نقل الكوليسترليستير اوكسازوليدينون ثمائي الحلقة
PH12014500912A1 (en) 2011-10-28 2014-06-09 Novartis Ag Novel purine derivatives and their use in the treatment of disease
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
AR088941A1 (es) 2011-11-23 2014-07-16 Bayer Ip Gmbh Anticuerpos anti-fgfr2 y sus usos
WO2013088191A1 (en) 2011-12-12 2013-06-20 Institut National De La Sante Et De La Recherche Medicale (Inserm) Antagonist of the fibroblast growth factor receptor 3 (fgfr3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of fgfr3
PT2824181T (pt) 2012-03-08 2018-12-20 Astellas Pharma Inc Novo produto de fusão de fgfr3
US9254288B2 (en) 2012-05-07 2016-02-09 The Translational Genomics Research Institute Susceptibility of tumors to tyrosine kinase inhibitors and treatment thereof
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
EP2871236A4 (en) 2012-07-05 2016-03-09 Nat Cancer Ct FGFR2 fusion
BR112015000203A2 (pt) 2012-07-09 2017-06-27 Coherus Biosciences Inc formulações de etanercept que exibem redução marcada em partículas sub-visíveis
CA2880013C (en) 2012-07-24 2022-11-29 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20150203589A1 (en) 2012-07-24 2015-07-23 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
US20140030259A1 (en) 2012-07-27 2014-01-30 Genentech, Inc. Methods of treating fgfr3 related conditions
CN107501413A (zh) 2012-09-27 2017-12-22 中外制药株式会社 Fgfr3融合基因和以其作为标靶的药物
ES2949394T3 (es) 2012-11-05 2023-09-28 Found Medicine Inc Moléculas de fusión novedosas y usos de las mismas
CN104955522A (zh) 2012-11-07 2015-09-30 梯瓦制药工业有限公司 拉喹莫德胺盐
CA3150658A1 (en) 2013-01-18 2014-07-24 Foundation Medicine, Inc. Methods of treating cholangiocarcinoma
EP2981621B1 (en) 2013-04-05 2019-05-22 Life Technologies Corporation Gene fusions
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
WO2014193229A2 (en) 2013-05-27 2014-12-04 Stichting Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Novel translocations in lung cancer
EP3007681A1 (en) 2013-06-14 2016-04-20 Synthon B.V. Stable and water soluble pharmaceutical compositions comprising pemetrexed
US20160129030A1 (en) 2013-06-14 2016-05-12 The Brigham And Women's Hospital, Inc. Treatment of mtor hyperactive related diseases and disorders
EP3019628A4 (en) 2013-07-12 2017-05-10 The Regents Of The University Of Michigan Recurrent gene fusions in cancer
JP2016527274A (ja) 2013-08-02 2016-09-08 イグナイタ インコーポレイテッド ＡＸＬ／ｃＭＥＴ阻害剤を単独または他の薬剤と組み合わせて用いて各種がんを治療する方法
US9221804B2 (en) 2013-10-15 2015-12-29 Janssen Pharmaceutica Nv Secondary alcohol quinolinyl modulators of RORγt
RU2715236C2 (ru) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Комбинации
HUE053653T2 (hu) 2014-03-26 2021-07-28 Astex Therapeutics Ltd FGFR inhibitor és IGF1R inhibitor kombinációi
JO3512B1 (ar) 2014-03-26 2020-07-05 Astex Therapeutics Ltd مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز
WO2016048833A2 (en) 2014-09-26 2016-03-31 Janssen Pharmaceutica Nv Use of fgfr mutant gene panels in identifying cancer patients that will be responsive to treatment with an fgfr inhibitor
JOP20200201A1 (ar) 2015-02-10 2017-06-16 Astex Therapeutics Ltd تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين
AU2016219917B2 (en) 2015-02-19 2021-12-16 Fusion Pharmaceuticals Inc. Methods, compositions, and kits for treatment of cancer
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
CN105030777B (zh) 2015-07-14 2017-07-21 中国人民解放军第三军医大学第三附属医院 增强alk‑tki疗效、延缓其耐药的复合物及其制剂
CN105147687A (zh) 2015-09-28 2015-12-16 青岛华之草医药科技有限公司 一种治疗白血病的药物达沙替尼组合物胶囊
JOP20190280A1 (ar) 2017-06-02 2019-12-02 Janssen Pharmaceutica Nv مثبطات fgfr2 لعلاج سرطان الأوعية الصفراوية

Also Published As

Publication number Publication date
MY196599A (en) 2023-04-20
CN113209102A (zh) 2021-08-06
JO3695B1 (ar) 2020-08-27
US20240000778A1 (en) 2024-01-04
IL281024A (en) 2021-04-29
AU2022291429B2 (en) 2025-04-03
EP3256109B1 (en) 2021-07-14
BR112017017009A2 (pt) 2018-04-10
MX2017010287A (es) 2018-02-09
EP3256109A1 (en) 2017-12-20
JP2018505193A (ja) 2018-02-22
HUE056761T2 (hu) 2022-03-28
AU2016218000B2 (en) 2020-07-09
CR20170411A (es) 2017-11-07
JP2021038241A (ja) 2021-03-11
IL310469B2 (en) 2025-10-01
TWI834020B (zh) 2024-03-01
LT3256109T (lt) 2021-08-25
IL310469A (en) 2024-03-01
JP2023011758A (ja) 2023-01-24
CY1124432T1 (el) 2022-07-22
TW202123939A (zh) 2021-07-01
JP6796588B2 (ja) 2020-12-09
SG11201706472RA (en) 2017-09-28
ES2883829T3 (es) 2021-12-09
SG10202000734YA (en) 2020-03-30
KR20170110145A (ko) 2017-10-10
IL253700A0 (en) 2017-09-28
US20210169877A1 (en) 2021-06-10
NI201700101A (es) 2018-01-02
CN107427511A (zh) 2017-12-01
MA41496B1 (fr) 2021-09-30
US11684620B2 (en) 2023-06-27
US20180021332A1 (en) 2018-01-25
MX2021004110A (es) 2021-06-15
IL253700B (en) 2021-03-25
CL2017002022A1 (es) 2018-02-16
NZ734516A (en) 2024-03-22
SMT202100450T1 (it) 2021-09-14
MX381504B (es) 2025-03-12
AU2016218000A1 (en) 2017-08-31
KR20240140190A (ko) 2024-09-24
BR112017017009B1 (pt) 2023-10-24
IL310469B1 (en) 2025-06-01
KR102708049B1 (ko) 2024-09-23
PH12017501421A1 (en) 2018-01-15
CN107427511B (zh) 2020-11-03
DK3256109T3 (da) 2021-08-09
PL3256109T3 (pl) 2021-11-15
PH12017501421B1 (en) 2022-08-10
TWI719960B (zh) 2021-03-01
JP7550831B2 (ja) 2024-09-13
SI3256109T1 (sl) 2021-11-30
WO2016128411A1 (en) 2016-08-18
US10898482B2 (en) 2021-01-26
AU2020250263A1 (en) 2020-11-05
TW201630608A (zh) 2016-09-01
EP3949954A1 (en) 2022-02-09
RS62221B1 (sr) 2021-09-30
UA123767C2 (uk) 2021-06-02
AU2022291429A1 (en) 2023-02-02
PH12021551589A1 (en) 2022-05-11
KR102900539B1 (ko) 2025-12-16
MA41496A (fr) 2017-12-19
CA2976356A1 (en) 2016-08-18
MA55571A (fr) 2022-02-09
CO2017008862A2 (es) 2018-02-20
HRP20211244T1 (hr) 2021-11-12

Similar Documents

Publication Publication Date Title
MX2021004110A (es) Composiciones farmaceuticas que comprenden n-(3,5- dimetoxifenil)-n'-(1-metiletil)-n-[3-(1-metil-1h- pirazol-4-il)quinoxalin-6-il]etano-1,2-diamina.
MX2021002321A (es) Nuevos metodos.
MX393855B (es) Terapia de combinación que comprende un inhibidor de raf y trametinib
MX387322B (es) Formulaciones de inhibidor de demetilasa 1 especifica para lisina (lsd1).
MX2017003102A (es) Formulacion para inhalacion liquida que comprende rpl554.
MX370099B (es) Combinación que comprende un inhibidor de fgfr y un inhibidor de cmet para el tratamiento del cáncer.
PH12021551302A1 (en) COMPOUNDS AND THEIR USE FOR THE TREATMENT OF a1-ANTITRYPSIN DEFICIENCY
SG11201912110YA (en) Novel peptide and pharmaceutical composition for treatment of eye diseases comprising same novel peptide as active ingredient
PH12020500542A1 (en) Dopamine-b-hydroxylase inhibitors
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
PH12020500120A1 (en) Pharmaceutical compositions
EA201791798A1 (ru) Фармацевтические композиции, включающие n-(3,5-диметоксифенил)-n'-(1-метилэтил)-n-[3-(1-метил-1h-пиразол-4-ил)хиноксалин-6-ил]этан-1,2-диамин
EA201992754A1 (ru) Фармацевтические композиции
HK1242618A1 (en) Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine